Last reviewed · How we verify
IDegAsp
IDegAsp is a fixed-ratio combination insulin that provides both long-acting basal insulin coverage and rapid-acting mealtime insulin in a single injection.
IDegAsp is a fixed-ratio combination insulin that provides both long-acting basal insulin coverage and rapid-acting mealtime insulin in a single injection. Used for Type 2 diabetes mellitus, Type 1 diabetes mellitus.
At a glance
| Generic name | IDegAsp |
|---|---|
| Sponsor | Sanofi |
| Drug class | Insulin combination (basal-bolus) |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
IDegAsp combines insulin degludec (a ultra-long-acting basal insulin) with insulin aspart (a rapid-acting insulin). Insulin degludec provides steady, 24-hour glucose control, while insulin aspart addresses postprandial (after-meal) glucose spikes. This combination allows patients to achieve glycemic control with a simplified twice-daily injection regimen.
Approved indications
- Type 2 diabetes mellitus
- Type 1 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Headache
Key clinical trials
- Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes (PHASE4)
- Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM (NA)
- iGlarLixi vs IDegAsp in Chinese Participants After OAD(s) (PHASE3)
- A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM (PHASE2)
- China Research of IDEgAsp Treatment in Real-world Clinical practicE (CREATE)
- Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM (NA)
- A Trial Investigating the Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart in Healthy Chinese Subjects (PHASE1)
- A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |